Cardiovascular Effects of Iron Deficiency in CKD Stage 2

Introduction to Iron Deficiency and Cardiovascular Risk

The American Society of Nephrology recommends that iron deficiency in CKD stage 2 significantly increases cardiovascular risk, including higher rates of cardiovascular hospitalizations, mortality, myocardial infarction, stroke, and heart failure, even when anemia is not present 1, 2, 3

Iron deficiency is independently associated with adverse cardiovascular outcomes in CKD patients, separate from its role in anemia, with increased cardiovascular hospitalizations and mortality 1, 2, 4
The National Kidney Foundation states that iron deficiency contributes to increased incidence of myocardial infarction, stroke, and heart failure hospitalizations 1, 5
The European Renal Association notes that impaired cardiac function occurs even without anemia, suggesting iron has direct effects on myocardial tissue beyond oxygen-carrying capacity 2, 6

The American Heart Association suggests that iron deficiency likely impairs cardiac function through multiple pathways, including reduced myocardial energy metabolism 1, 2
Iron is essential for mitochondrial function and cellular energy production in cardiac myocytes, according to the American College of Cardiology 2, 6

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines state that between 15-72.8% of non-dialysis CKD patients have either ferritin <100 μg/L or TSAT <20%, with 8-20% having both parameters below threshold 3
Iron deficiency prevalence increases with advancing CKD stages, as noted by the National Institute of Diabetes and Digestive and Kidney Diseases 3, 7

The European Society of Cardiology recommends that correcting iron deficiency improves cardiovascular outcomes in CKD patients, with benefits seen regardless of anemia status 2, 8
Multiple RCTs demonstrate that IV iron in heart failure patients with iron deficiency improves exercise capacity, quality of life, NYHA class, and reduces hospitalizations, according to the American College of Cardiology 2, 5, 8

The National Kidney Foundation suggests screening for iron deficiency using transferrin saturation and ferritin levels, with absolute iron deficiency defined as TSAT ≤20% and ferritin <100 μg/L in non-dialysis CKD patients 3
Functional iron deficiency is defined as TSAT ≤20% with ferritin >100 μg/L, often due to inflammation and hepcidin-mediated iron sequestration, as noted by the European Renal Association 3

Ferritin is an acute phase reactant and may be falsely elevated in inflammatory states, according to the American Society of Nephrology 3, 9
The truly independent cardiovascular risk of iron deficiency remains somewhat uncertain due to confounding comorbidities, as stated by the National Institute of Diabetes and Digestive and Kidney Diseases 1, 2, 4